We are delighted to be collaborating with leading biotechnology company Amgen – World Child Cancer
Quoting World Child Cancer on LinkedIn:
“We are delighted to be collaborating with leading biotechnology company Amgen to launch a multi-year program aimed at saving and improving the lives of children with cancer in low- and middle-income countries (LMICs) in Africa and Asia. This project will centre its attention on improving outcomes for children with cancer in five target countries.
Children in LMICs face disproportionately low cancer survival rates. According to the World Health Organisation, only 15-45% of children in LMICs survive their cancer, compared with more than 80% in high-income countries.
The new collaboration aims to tackle this disparity, focusing on children with Burkitt Lymphoma, in five target countries. The collaboration will fund training for healthcare professionals to deliver treatment as well as holistic psychosocial support for children as they are being diagnosed, in treatment, in recovery and reintegrating into school. Where appropriate, Amgen will also provide relevant oncology medications. The program will help to create sustainable health systems to ensure new medicines can be used safely and effectively.
We look forward to sharing our updates with you!”
Source: World Child Cancer/LinkedIn
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023